Main Menu

Prostate Cancer Targeted Therapy Group 

Professor Johann de Bono’s team investigates new molecular targeted therapies to improve the treatment of patients with advanced prostate cancer.

Team leader

Professor Johann de Bono

Professor Johann de Bono

Regius Professor of Cancer Research

Professor Johann de Bono is Head of the Division of Clinical Studies and an international expert in the development of molecularly targeted cancer therapies against adult cancers. He runs one of the world’s largest phase I clinical trials units for cancer and has also led phase III trials of the prostate cancer drugs abiraterone and cabazitaxel.

ORCID 0000-0002-2034-595X